Activation of rapid signaling pathways does not contribute to 1α,25-dihydroxyvitamin D3-induced growth inhibition of mouse prostate epithelial progenitor cells

Journal of Cellular Biochemistry

Volumn 107, Issue 5, 2009, Pages 1031-1036

  Li, Jia ^a   Fleet, James C ^a   Teegarden, Dorothy ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

1,25 dihydroxyvitamin D; Growth inhibition; MAPK; Prostate; Protein kinase C; Vitamin D

Indexed keywords

CALCITRIOL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE C ALPHA;

ANIMAL CELL; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; GROWTH INHIBITION; IMMUNOBLOTTING; INCUBATION TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE EPITHELIUM; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; STEM CELL;

ANIMALS; CELL PROLIFERATION; EPITHELIAL CELLS; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROSTATE; PROTEIN KINASE C-ALPHA; SIGNAL TRANSDUCTION; STEM CELLS; VITAMIN D;

EID: 67749114325     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22206     Document Type: Article

References (41)

1. Balogh G, Boland R, de Boland AR. 2000. 1,25(OH)(2)-vitamin D(3) affects the subcellular distribution of protein kinase C isoenzymes in rat duodenum: Influence of aging. J Cell Biochem 79:686-694.
2. Barclay WW, Cramer SD. 2005. Culture of mouse prostatic epithelial cells from genetically engineered mice. Prostate 63:291-298.
3. Barclay WW, Axanova LS, Chen W, Romero L, Maund SL, Soker S, Lees CJ, Cramer SD. 2008. Characterization of adult prostatic progenitor/stem cells exhibiting self-renewal and multilineage differentiation. Stem Cells 26(3): 600-610.
4. Beno DW, Brady LM, Bissonnette M, Davis BH. 1995. Protein kinase C and mitogen-activated protein kinase are required for 1,25-dihydroxyvitamin D3-stimulated Egr induction. J Biol Chem 270:3642-3647.
5. Blutt SE, Allegretto EA, Pike JW, Weigel NL. 1997. 1,25-Dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 138: 1491-1497.
6. Bonkhoff H. 1996. Role of the basal cells in premalignant changes of the human prostate is from a small prostate stem cell population. Eur Urol 30(2): 201-205.
7. Boyan BD, Sylvia VL, McKinney N, Schwartz Z. 2003. Membrane actions of vitamin D metabolites 1alpha,25(OH)2D3 and 24R,25(OH)2D3 are retained in growth plate cartilage cells from vitamin D receptor knockout mice. J Cell Biochem 90:1207-1223.
8. Breitkreutz D, Braiman-Wiksman L, Daum N, Denning MF, Tennenbaum T. 2007. Protein kinase C family: On the crossroads of cell signaling in skin and tumor epithelium. J Cancer Res Clin Oncol 133:793-808.
9. Buitrago C, Boland R, de Boland AR. 2001a. The tyrosine kinase c-Src is required for 1,25(OH)2-vitamin D3 signalling to the nucleus in muscle cells. Biochim Biophys Acta 1541:179-187.
10. Buitrago C, Vazquez G, De Boland AR, Boland R. 2001b. The vitamin D receptor mediates rapid changes in muscle protein tyrosine phosphorylation induced by 1,25(OH)(2)D(3). Biochem Biophys Res Commun 289:1150-1156.
11. Capiati DA, Vazquez G, Tellez Inon MT, Boland RL. 2000. Role of protein kinase C in 1,25(OH)(2)-vitamin D(3) modulation of intracellular calcium during development of skeletal muscle cells in culture. J Cell Biochem 77: 200-212.
12. Capiati DA, Rossi AM, Picotto G, Benassati S, Boland RL. 2004. Inhibition of serum-stimulated mitogen activated protein kinase by 1alpha,25(OH)2-vitamin D3 in MCF-7 breast cancer cells. J Cell Biochem 93:384-397.
13. Chen A, Davis BH, Bissonnette M, Scaglione-Sewell B, Brasitus TA. 1999. 1,25-Dihydroxyvitamin D(3) stimulates activator protein-1-dependent Caco-2 cell differentiation. J Biol Chem 274:35505-35513.
14. Cordes T, Diesing D, Becker S, Diedrich K, Reichrath J, Friedrich M. 2006. Modulation of MAPK ERK1 and ERK2 in VDR-positive and -negative breast cancer cell lines. Anticancer Res 26(4A): 2749-2753.
15. Farach-Carson MC, Davis PJ. 2003. Steroid hormone interactions with target cells: Cross talk between membrane and nuclear pathways. J Pharmacol Exp Ther 307:839-845.
16. Galbiati F, Polastri L, Gregori S, Freschi M, Casorati M, Cavallaro U, Fiorina P, Bertuzzi F, Zerbi A, Pozza G, Adorini L, Folli F, Christofori G, Davalli AM. 2002. Antitumorigenic and antiinsulinogenic effects of calcitriol on insulinoma cells and solid beta-cell tumors. Endocrinology 143:4018-4030.
17. Huhtakangas JA, Olivera CJ, Bishop JE, Zanello LP, Norman AW. 2004. The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1 alpha,25(OH)2-vitamin D3 in vivo and in vitro. Mol Endocrinol 18: 2660-2671.
18. Johansen C, Kragballe K, Henningsen J, Westergaard M, Kristiansen K, Iversen L. 2003. 1alpha,25-dihydroxyvitamin D3 stimulates activator protein 1 DNA-binding activity by a phosphatidylinositol 3-kinase/Ras/MEK/ extracellular signal regulated kinase 1/2 and c-Jun N-terminal kinase 1-dependent increase in c-Fos, Fra1, and c-Jun expression in human keratinocytes. J Invest Dermatol 120:561-570.
19. Khanal RC, Nemere I. 2007. The ERp57/GRp58/1,25D3-MARRS receptor: Multiple functional roles in diverse cell systems. Curr Med Chem 14(10): 1087-1093.
20. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. 1996. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10:142-153.
21. Maitland NJ, Bryce SD, Stower MJ, Collins AT. 2006. Prostate cancer stem cells: A target for new therapies. Ernst Schering Found Symp Proc 5:155-179.
22. Marcinkowska E, Wiedlocha A, Radzikowski C. 1997. 1,25-Dihydroxyvitamin D3 induced activation and subsequent nuclear translocation of MAPK is upstream regulated by PKC in HL-60 cells. Biochem Biophys Res Commun 241:419-426.
23. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P. 1992. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res 52:515-520.
24. Morelli S, Buitrago C, Boland R, de Boland AR. 2001. The stimulation of MAP kinase by 1,25(OH)(2)-vitamin D(3) in skeletal muscle cells is mediated by protein kinase C and calcium. Mol Cell Endocrinol 173: 41-52.
25. Pardo VG, de Boland AR. 2004. Tyrosine phosphorylation signalling dependent on 1alpha,25(OH)2-vitamin D3 in rat intestinal cells: Effect of ageing. Int J Biochem Cell Biol 36:489-504.
26. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. 1994. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 54:805-810.
27. Rao A, Woodruff RD, Wade WN, Kute TE, Cramer SD. 2002. Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth. J Nutr 132:3191-3194.
28. Rao A, Coan A, Welsh JE, Barclay WW, Koumenis C, Cramer SD. 2004. Vitamin D receptor and p21/WAF1 are targets of genistein and 1,25-dihydroxyvitamin D3 in human prostate cancer cells. Cancer Res 64: 2143-2147.
29. Rivera-Bermudez MA, Bertics PJ, Albrecht RM, Mosavin R, Mellon WS. 2002. 1,25-Dihydroxyvitamin D3 selectively translocates PKCalpha to nuclei in ROS 17/2.8 cells. Mol Cell Endocrinol 188:227-239.
30. Saramaki A, Banwell CM, Campbell MJ, Carlberg C. 2006. Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res 34:543-554.
31. Schwartz GG, Hulka BS. 1990. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10:1307-1311.
32. Schwartz Z, Ehland H, Sylvia VL, Larsson D, Hardin RR, Bingham V, Lopez D, Dean DD, Boyan BD. 2002. 1alpha,25-dihydroxyvitamin D(3) and 24R,25-dihydroxyvitamin D(3) modulate growth plate chondrocyte physiology via protein kinase C-dependent phosphorylation of extracellular signalregulated kinase 1/2 mitogen-activated protein kinase. Endocrinology 143:2775-2786.
33. Schwartz Z, Shaked D, Hardin RR, Gruwell S, Dean DD, Sylvia VL, Boyan BD. 2003. 1alpha,25(OH)2D3 causes a rapid increase in phosphatidylinositol-specific PLC-beta activity via phospholipase A2-dependent production of lysophospholipid. Steroids 68:423-437.
34. Skowronski RJ, Peehl DM, Feldman D. 1993. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952-1960.
35. Skowronski RJ, Peehl DM, Feldman D. 1995. Actions of vitamin D3, analogs on human prostate cancer cell lines: Comparison with 1,25-dihydroxyvitamin D3. Endocrinology 136:20-26.
36. Song X, Bishop JE, Okamura WH, Norman AW. 1998. Stimulation of phosphorylation of mitogen-activated protein kinase by 1alpha,25- dihydroxyvitamin D3 in promyelocytic NB4 leukemia cells: A structurefunction study. Endocrinology 139:457-465.
37. Sprenger CC, Peterson A, Lance R, Ware JL, Drivdahl RH, Plymate SR. 2001. Regulation of proliferation of prostate epithelial cells by 1,25-dihydroxyvitamin D3 is accompanied by an increase in insulin-like growth factor binding protein-3. J Endocrinol 170:609-618.
38. Stewart LV, Weigel NL. 2005. Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells. Prostate 64(1): 9-19.
39. Wali RK, Kong J, Sitrin MD, Bissonnette M, Li YC. 2003. Vitamin D receptor is not required for the rapid actions of 1,25-dihydroxyvitamin D3 to increase intracellular calcium and activate protein kinase C in mouse osteoblasts. J Cell Biochem 88:794-801.
40. Wu W, Zhang X, Zanello LP. 2007. 1alpha,25-Dihydroxyvitamin D(3) anti-proliferative actions involve vitamin D receptor-mediated activation of MAPK pathways and AP-1/p21(waf1) upregulation in human osteosarcoma. Cancer Lett 254(1):75-86.
41. Zhuang SH, Burnstein KL. 1998. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139:1197-1207.